‘Did He Who Made the Lamb Make Thee?’ New Developments in Treating the ‘Fearful Symmetry’ of Acute Myeloid Leukemia

Gabriela Brumatti, Najoua Lalaoui, Andrew H. Wei, John Silke

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Malignant cells must circumvent endogenous cell death pathways to survive and develop into cancers. Acquired cell death resistance also sets up malignant cells to survive anticancer therapies. Acute Myeloid Leukemia (AML) is an aggressive blood cancer characterized by high relapse rate and resistance to cytotoxic therapies. Recent collaborative profiling projects have led to a greater understanding of the ‘fearful symmetry’ of the genomic landscape of AML, and point to the development of novel potential therapies that can overcome factors linked to chemoresistance. We review here the most recent research in the genetics of AML and how these discoveries have led, or might lead, to therapies that specifically activate cell death pathways to substantially challenge this ‘fearful’ disease.

Original languageEnglish
Pages (from-to)264-281
Number of pages18
JournalTrends in Molecular Medicine
Volume23
Issue number3
DOIs
Publication statusPublished - 1 Mar 2017

Cite this

@article{5ac8cf184b774d829f05d2ef8a073eda,
title = "‘Did He Who Made the Lamb Make Thee?’ New Developments in Treating the ‘Fearful Symmetry’ of Acute Myeloid Leukemia",
abstract = "Malignant cells must circumvent endogenous cell death pathways to survive and develop into cancers. Acquired cell death resistance also sets up malignant cells to survive anticancer therapies. Acute Myeloid Leukemia (AML) is an aggressive blood cancer characterized by high relapse rate and resistance to cytotoxic therapies. Recent collaborative profiling projects have led to a greater understanding of the ‘fearful symmetry’ of the genomic landscape of AML, and point to the development of novel potential therapies that can overcome factors linked to chemoresistance. We review here the most recent research in the genetics of AML and how these discoveries have led, or might lead, to therapies that specifically activate cell death pathways to substantially challenge this ‘fearful’ disease.",
author = "Gabriela Brumatti and Najoua Lalaoui and Wei, {Andrew H.} and John Silke",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.molmed.2017.01.005",
language = "English",
volume = "23",
pages = "264--281",
journal = "Trends in Molecular Medicine",
issn = "1471-4914",
publisher = "Elsevier",
number = "3",

}

‘Did He Who Made the Lamb Make Thee?’ New Developments in Treating the ‘Fearful Symmetry’ of Acute Myeloid Leukemia. / Brumatti, Gabriela; Lalaoui, Najoua; Wei, Andrew H.; Silke, John.

In: Trends in Molecular Medicine, Vol. 23, No. 3, 01.03.2017, p. 264-281.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - ‘Did He Who Made the Lamb Make Thee?’ New Developments in Treating the ‘Fearful Symmetry’ of Acute Myeloid Leukemia

AU - Brumatti, Gabriela

AU - Lalaoui, Najoua

AU - Wei, Andrew H.

AU - Silke, John

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Malignant cells must circumvent endogenous cell death pathways to survive and develop into cancers. Acquired cell death resistance also sets up malignant cells to survive anticancer therapies. Acute Myeloid Leukemia (AML) is an aggressive blood cancer characterized by high relapse rate and resistance to cytotoxic therapies. Recent collaborative profiling projects have led to a greater understanding of the ‘fearful symmetry’ of the genomic landscape of AML, and point to the development of novel potential therapies that can overcome factors linked to chemoresistance. We review here the most recent research in the genetics of AML and how these discoveries have led, or might lead, to therapies that specifically activate cell death pathways to substantially challenge this ‘fearful’ disease.

AB - Malignant cells must circumvent endogenous cell death pathways to survive and develop into cancers. Acquired cell death resistance also sets up malignant cells to survive anticancer therapies. Acute Myeloid Leukemia (AML) is an aggressive blood cancer characterized by high relapse rate and resistance to cytotoxic therapies. Recent collaborative profiling projects have led to a greater understanding of the ‘fearful symmetry’ of the genomic landscape of AML, and point to the development of novel potential therapies that can overcome factors linked to chemoresistance. We review here the most recent research in the genetics of AML and how these discoveries have led, or might lead, to therapies that specifically activate cell death pathways to substantially challenge this ‘fearful’ disease.

UR - http://www.scopus.com/inward/record.url?scp=85012014499&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2017.01.005

DO - 10.1016/j.molmed.2017.01.005

M3 - Review Article

VL - 23

SP - 264

EP - 281

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

IS - 3

ER -